<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04364503</url>
  </required_header>
  <id_info>
    <org_study_id>SCMM-RND-402</org_study_id>
    <nct_id>NCT04364503</nct_id>
  </id_info>
  <brief_title>Compliant Analysis of Patient Samples and Data</brief_title>
  <official_title>Use of Patient Samples and Corresponding Clinical Data for Research and Development Studies and/or Population-based Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sequenom, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sequenom, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients of scientific interest who have provided a commercial sample to LabCorp or one of
      its' affiliates will have their de-identified remnant samples and/or data used for research
      and development. Other commercial patients will be followed up on after informed consent is
      obtained.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Arm 1 - Remnant commercial samples and data that has been de-identified of personal health
      information in compliance with HIPAA may be used for R&amp;D studies or population-based analysis
      by LabCorp or affiliates.

      Arm 2 - Collection of samples and/or data from commercial test patients requiring follow-up
      or from subjects of scientific interest after informed consent is obtained.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 17, 2018</start_date>
  <completion_date type="Anticipated">August 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 17, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Remnant samples and data for research and development</measure>
    <time_frame>Retrospective and Prospective collection. Samples and data may be collected for up 12 months after enrollment.</time_frame>
    <description>Remnant samples and data for research and development</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sample and data collection from subjects of scientific interest</measure>
    <time_frame>Prospective collection. Samples and data may be collected for up to 12 months after enrollment</time_frame>
    <description>Collect additional clinical data and samples if needed from subjects tested by LabCorp or an affiliate.</description>
  </primary_outcome>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Pregnancy Related</condition>
  <condition>Cancer</condition>
  <condition>Infectious Disease</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Multiple interventions depending on diagnostic test being run.</intervention_name>
    <description>Remnant samples and corresponding data from multiple diagnostic tests will be stored for future research and development.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Commercial remnant samples stored at multiple LabCorp affiliates.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Arm 1 - Female or male patient samples submitted to Sequenom or LabCorp affiliate for
        routine clinical care testing that no longer need to be maintained for clinical purposes.

        Arm 2 - Female or male subjects of scientific interest who have provided written informed
        consent/assent.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Arm 1

          -  All samples and data are de-identified and HIPAA compliant

          -  Arm 2

          -  Subject is of scientific interest to the Sponsor or treating physician

          -  Subject provides written informed consent and has a clinical sample and/or supporting
             clinical data collected.

        Exclusion Criteria:

          -  Arm 1

          -  Subject is from a US state or a country where local law restricts the use of
             de-identified data and/or remnants of specimens for research and/or development

          -  Arm 2

          -  Any medical or mental condition that would interfere with the subjects' ability to
             willingly give written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Graham P McLennan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sequenom, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Graham P Senior Director</last_name>
    <phone>(858) 202-2000</phone>
    <email>mclenng@labcorp.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sequenom, Inc</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Graham P McLennan, MS</last_name>
      <phone>858-202-2000</phone>
      <email>mclenng@labcorp.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 22, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2020</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

